Search results for "drug discovery"

showing 10 items of 3927 documents

SUBFRACTIONS AND SUBPOPULATIONS OF HDL: AN UPDATE

2014

High-density lipoproteins (HDL) are classified as atheroprotective because they are involved in transport of cholesterol to the liver, known as "reverse cholesterol transport (RCT)" exerting antioxidant and anti-inflammatory activities. There is also evidence for cytoprotective, vasodilatory, antithrombotic, and anti-infectious activities for these lipoproteins. HDLs are known by structural, metabolic and biologic heterogeneity. Thus, different methods are able to distinguish several subclasses of HDL. Different separation techniques appear to support different HDL fractions as being atheroprotective or related with lower cardiovascular (CV) risk. However, HDL particles are not always prote…

medicine.medical_specialtyPharmacologyBiologySystemic inflammationBiochemistrychemistry.chemical_compoundRisk FactorsInternal medicineDrug DiscoveryAntithromboticmedicineAnimalsHumansHdl functionalityPharmacologyCholesterolOrganic ChemistryReverse cholesterol transportBiomarker (cell)EndocrinologychemistryCardiovascular DiseasesMolecular MedicineSeparation methodlipids (amino acids peptides and proteins)Hdl subfractionscardiovascular risk electrophoresis high-density lipoprotein nuclear magnetic resonance proteome subclasses subfractions ultracentrifugation.medicine.symptomLipoproteins HDL
researchProduct

Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebo-controlled trial.

2011

Crataegus laevigata is a medicinal plant most commonly used for the treatment of heart failure and psychosomatic disorders. Based on previous experimental findings, this double-blind placebo-controlled study was aimed at finding beneficial effects of C. laevigata on biomarkers of coronary heart disease (CHD). The study included 49 diabetic subjects with chronic CHD who were randomly assigned to the treatment for 6 months with either a micronized flower and leaf preparation of C. laevigata (400 mg three times a day) or a matching placebo. Blood cell count, lipid profile, C-reactive protein, neutrophil elastase (NE) and malondialdehyde were analyzed in plasma at baseline, at one month and six…

medicine.medical_specialtyPlacebo-controlled studyPharmaceutical ScienceCoronary DiseaseFlowersPlaceboGastroenterologyDiabetes Complicationschemistry.chemical_compoundDouble-Blind MethodInterquartile rangeInternal medicineDiabetes mellitusDrug DiscoverymedicineHumansAgedPharmacologyCrataegusmedicine.diagnostic_testbiologybusiness.industryCholesterolPlant ExtractsC-reactive proteinCholesterol LDLMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryCrataegus laevigataPlant LeavesC-Reactive ProteinComplementary and alternative medicinechemistryDiabetes Mellitus Type 2biology.proteinMolecular MedicineLipid PeroxidationLipid profilebusinessLeukocyte ElastasePhytotherapyPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repagl…

2004

The 11 C-labeled sulfonylurea receptor 1 (SUR1) ligand (S)-2-(( 11 C)methoxy)-4-(3-methyl-1-(2-piperidine-1-yl-phenyl)- butyl-carbamoyl)-benzoic acid (( 11 C)methoxy-repaglinide) was synthesized in an overall radiochemical yield of 35% after 55 min with a radiochemical purity higher than 99%. This compound is considered for the noninvasive investigation of the SUR1 receptor status of pancreatic b-cells by positron emission tomography (PET) in the context of type 1 and type 2 diabetes. The specific activity was 40-70 GBq/lmol. In vitro testing of the nonradioactive methoxy-repaglinide was performed to characterize the affinity for binding to the human SUR1 isoform. Methoxy-repaglinide induce…

medicine.medical_specialtyPotassium Channelsmedicine.medical_treatmentReceptors DrugClinical BiochemistryPharmaceutical ScienceType 2 diabetesIn Vitro TechniquesSulfonylurea ReceptorsBiochemistryBenzoatesBinding CompetitiveIslets of LangerhansPiperidinesDiabetes mellitusInternal medicineDrug DiscoveryInsulin SecretionmedicineAnimalsHumansInsulinCarbon RadioisotopesPotassium Channels Inwardly RectifyingMolecular BiologyIC50Type 1 diabetesChemistryInsulinOrganic ChemistryStereoisomerismmedicine.diseaseRepaglinideLigand (biochemistry)RatsEndocrinologyPositron-Emission TomographyCOS CellsMolecular MedicineSulfonylurea receptorATP-Binding Cassette TransportersCarbamatesRadiopharmaceuticalsHydroxybenzoate Ethersmedicine.drugBioorganicmedicinal chemistry letters
researchProduct

Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System

2009

Nitric oxide (NO) produced by endothelial NO synthase (eNOS) represents an anti-atherosclerotic principle. NO bioavailability is decreased in atherosclerosis due to increased NO inactivation by reactive oxygen species and reduced NO synthesis. Various types of vascular pathophysiology are associated with oxidative stress, with NADPH oxidases as the major source of reactive oxygen species. These inactivate NO. Also, oxidative stress is likely to be the main cause for oxidation of the essential NOS cofactor, tetrahydrobiopterin (BH(4)). A lack of BH(4) leads to eNOS uncoupling (i.e., uncoupling of oxygen reduction from NO synthesis in eNOS). Based on these pathomechanisms, the therapeutic pot…

medicine.medical_specialtySepiapterinNitric Oxide Synthase Type IIImedicine.drug_classGTP cyclohydrolase INitric Oxidemedicine.disease_causeRenin inhibitorNitric oxidechemistry.chemical_compoundEnosInternal medicineDrug DiscoverymedicineAnimalsHumansHypolipidemic AgentsPharmacologybiologyArteriesTetrahydrobiopterinAtherosclerosisbiology.organism_classificationNitric oxide synthaseOxidative StressTreatment OutcomeEndocrinologychemistrybiology.proteinOxidative stressSignal Transductionmedicine.drugCurrent Pharmaceutical Design
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

Antiplatelet treatment in ischemic stroke treatment.

2009

Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity through a variety of mechanisms. Antithrombotic agents are effective in the secondary prevention of ischemic strokes. Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot. Immediate treatment with antiplatelet drugs such as aspirin may prevent new clots from forming and hence improve recovery after stroke. Several studies have evaluated the role of one antiplatelet agent, aspirin, in reducing stroke severity. The International Stroke Trial (IST) of 20,000 patients with acute stroke from other countries. In thi…

medicine.medical_specialtySettore MED/09 - Medicina InternaTiclopidineBrain IschemiaInternal medicineDrug DiscoveryAntithromboticmedicineHumanscardiovascular diseasesPlatelet activationTiclopidineStrokeAspirinAspirinbusiness.industryGeneral Medicinemedicine.diseaseClopidogrelSurgeryClopidogrelStrokemedicine.anatomical_structureToxicityCardiologyantiplatelets strokeprevention treatmentbusinessPlatelet Aggregation Inhibitorsmedicine.drugArteryCurrent topics in medicinal chemistry
researchProduct

Indomethacin treatment in amphotericin B induced nephrogenic diabetes insipidus.

1994

Nephrogenic diabetes insipidus (NDI) is a serious side effect of various drugs. Elevated renal prostaglandin E2 levels have been found in patients with lithium-induced NDI and have been implicated in the pathogenesis. We report the case of a patient who developed NDI following treatment with amphotericin B. Prostaglandin levels were elevated. Indomethacin had an antidiuretic effect and normalized prostaglandin levels.

medicine.medical_specialtySide effectVasopressinsIndomethacinProstaglandinDiabetes Insipidus NephrogenicKidneyLeukemia Myelomonocytic AcutePathogenesischemistry.chemical_compoundAmphotericin BInternal medicineAmphotericin BDrug DiscoveryMedicineHumansProstaglandin E2Genetics (clinical)business.industryGeneral MedicineMiddle Agedmedicine.diseaseNephrogenic diabetes insipidusDiuresisEndocrinologychemistryDiabetes insipidusToxicityProstaglandinsTobramycinMolecular Medicinelipids (amino acids peptides and proteins)Femalebusinessmedicine.drugThe Clinical investigator
researchProduct

A body weight loss- and health-promoting gut microbiota is established after bariatric surgery in individuals with severe obesity

2020

Obesity has reached an epidemic level worldwide, and bariatric surgery (BS) has been proven to be the most efficient therapy to reduce severe obesity-related comorbidities. Given that the gut microbiota plays a causal role in obesity development and that surgery may alter the gut environment, investigating the impact of BS on the microbiota in the context of severe obesity is important. Although, alterations at the level of total gut bacteria, total gene content and total metabolite content have started to be disentangled, a clear deficit exists regarding the analysis of the active fraction of the microbiota, which is the fraction that is most reactive to the BS. Here, active gut microbiota…

medicine.medical_specialtySleeve gastrectomymedicine.medical_treatmentClinical BiochemistryGastric BypassPharmaceutical ScienceBariatric SurgeryContext (language use)Gut flora01 natural sciencesAnalytical ChemistryMetabolomicsDetoxificationDrug DiscoveryWeight LossmedicineHumansMicrobiomeSpectroscopybiology010405 organic chemistryChemistry010401 analytical chemistryMetabolismmedicine.diseasebiology.organism_classificationObesity0104 chemical sciencesSurgeryGastrointestinal MicrobiomeObesity Morbid
researchProduct

An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich

2007

Low density lipoproteins (LDL) size seems to be an important predictor of cardiovascular events and progression of coronary artery disease and the predominance of small dense LDL have been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. We recently showed increased LDL size or higher levels of small, dense LDL in different categories of patients at higher cardiovascular risk, such as those with coronary (including acute myocardial infarction) and non-coronary (including carotid disease, abdominal aortic aneurysm and peripheral arterial disease) forms of atherosclerosis or metabolic diseases (including type-II diabet…

medicine.medical_specialtyStatinUniversitiesmedicine.drug_classCoronary artery diseaseEzetimibeInternal medicineDrug DiscoverymedicineHumansPharmacology (medical)RosuvastatinCholesterol absorption inhibitorParticle SizeRisk factorNational Cholesterol Education Programbusiness.industrymedicine.diseasePolycystic ovaryLipoproteins LDLItalyCardiovascular DiseasesCardiologylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessSwitzerlandmedicine.drugRecent Patents on Cardiovascular Drug Discovery
researchProduct

The pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder dis…

2014

Highlights • Muscarinic receptors increase smooth muscle tone in airways and urinary bladder. • β-Adrenoceptors relax smooth muscle tone and oppose muscarinic contraction. • Opposition involves transmitter release, signal transduction and receptor expression. • This supports the combined use of muscarinic antagonists and β-adrenoceptor agonists.

medicine.medical_specialtyUrologyDiseaseMuscarinic AntagonistsPharmacologyArticleβ adrenoceptorchemistry.chemical_compoundInternal medicineReceptors Adrenergic betaMuscarinic acetylcholine receptorDrug DiscoveryMuscarinic acetylcholine receptor M4RAT URINARY-BLADDERMedicineAnimalsHumansCyclic adenosine monophosphateADRENERGIC RELAXATIONLung Diseases ObstructivePROTEIN-KINASE-CReceptorTRACHEAL SMOOTH-MUSCLEPharmacologybusiness.industryUrinary Bladder DiseasesMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2ACETYLCHOLINE-RELEASEAdrenergic beta-Agonistsmedicine.diseaseReceptors MuscarinicEndocrinologyNONNEURONAL CHOLINERGIC SYSTEMchemistryGUINEA-PIG TRACHEADrug Therapy CombinationCYCLIC ADENOSINE-MONOPHOSPHATECA2+-ACTIVATED K+ CHANNELAirwaybusinessUrinary bladder diseaseAUTORADIOGRAPHIC VISUALIZATIONAcetylcholinemedicine.drug
researchProduct